MAAB

16/06/2026

🚀 Growing Clinical Adoption of SANCUSO® Across China

The momentum behind SANCUSO® in China continues to build.

Over the past year, we have witnessed increasing interest from oncology centers, healthcare professionals, and patients seeking effective supportive care solutions for chemotherapy-related nausea and vomiting.

As clinical experience grows, SANCUSO® is being adopted by an expanding number of hospitals, reflecting strong confidence in its unique transdermal delivery platform and patient-friendly treatment approach.

The positive market response reinforces our commitment to making innovative oncology supportive care therapies more accessible throughout Greater China.

We thank our partners, clinicians, and patients for their continued trust and support.

05/06/2026

🇨🇳 Is China preparing to accelerate pharmaceutical API localization?

China’s NMPA has released a draft proposal that would grant priority review to certain Active Pharmaceutical Ingredients (APIs), including the first domestic registration of APIs developed as alternatives to imported products.

While this may appear to be a technical regulatory update, it could have much broader implications for:

🔹 Global API manufacturers
🔹 Pharmaceutical supply chains
🔹 China market access strategies
🔹 Long-term competitiveness in the life sciences sector

As China continues to strengthen its domestic pharmaceutical ecosystem, international companies should pay close attention to how these policy developments may impact their future business in the market.

We’ve shared our thoughts in our latest article:

👉 https://www.maab-group.com/post/china-s-proposed-api-priority-review-policy-china-s-localization-strategy-expands-into-apis

At MAAB, we help pharmaceutical and healthcare companies understand not only regulatory changes in China, but also the commercial opportunities and risks that sit behind them.

We would be interested to hear your views:
Do you see this as a regulatory efficiency measure, an industrial policy initiative, or both?

On 2 June 2026, China's National Medical Products Administration (NMPA) released a draft proposal for public consultation that would grant priority review status to certain active pharmaceutical ingredients (APIs).The draft proposal outlines three circumstances under which an API may qualify for pri...